| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $67.04 | $14.25B | N/A |
Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
http://www.zacks.com/stock/news/336981/mercks-mrk-keytruda-gets-fda-approval-for-liver-cancer?cid=CS-ZC-FT-336981
Nov 12, 2018 - Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
0
Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript
https://www.fool.com/earnings/call-transcripts/2018/10/30/incyte-corp-incy-q3-2018-earnings-conference-call.aspx?source=iedfolrf0000001
Oct 30, 2018 - INCY earnings call for the period ending September 30, 2018.
0
Incyte (INCY) Q3 2018 Results - Earnings Call Transcript
https://seekingalpha.com/article/4215968-incyte-incy-q3-2018-results-earnings-call-transcript?source=feed_sector_healthcare
Oct 30, 2018 -
0
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
http://www.zacks.com/stock/news/330810/biotech-stock-roundup-biib-tops-mack-plunges-regns-asthma-drug-gets-fda-nod?cid=CS-ZC-FT-330810
Oct 24, 2018 - Earnings releases and key data-read outs were the key developments in the biotech sector last week.
0
2 Stocks That Could Benefit Big From Geron's Stumble
https://www.fool.com/investing/2018/09/29/2-stocks-that-could-benefit-big-from-gerons-stumbl.aspx?source=iedfolrf0000001
Sep 29, 2018 - A disappointing decision could mean one fewer competitor for these biotech companies.
0
Merck Gets Priority Review for Yet Another Keytruda sBLA
http://www.zacks.com/stock/news/322981/merck-gets-priority-review-for-yet-another-keytruda-sbla?cid=CS-ZC-FT-322981
Sep 13, 2018 - Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.
0
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
http://www.zacks.com/stock/news/322780/biotech-stock-roundup-gilds-arthritis-drug-successful-in-phase-iii-prqr-soars?cid=CS-ZC-FT-322780
Sep 12, 2018 - Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
0
Incyte, Foundation Medicine Partner for Companion Diagnostics
http://www.zacks.com/stock/news/322760/incyte-foundation-medicine-partner-for-companion-diagnostics?cid=CS-ZC-FT-322760
Sep 12, 2018 - Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
0
Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe
http://www.zacks.com/stock/news/322513/mercks-keytruda-combo-gets-nod-for-lung-cancer-in-europe?cid=CS-ZC-FT-322513
Sep 11, 2018 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
0
Merck's Keytruda Gets Priority Review for Rare Skin Cancer
http://www.zacks.com/stock/news/321571/mercks-keytruda-gets-priority-review-for-rare-skin-cancer?cid=CS-ZC-FT-321571
Sep 05, 2018 - Merck's (MRK) sBLA for Keytruda to expand its label for a rare form of skin cancer gets priority review from FDA.
0